Medical device company Contraline became the first to implant a hydrogel-based male contraceptive gel into humans in a clinical trial. Implanted during a noninvasive 10-minute office procedure, the gel promises to block the flow of sperm to the vas deferens. If proven safe and effective, it could become the first nonhormonal, reversible contraceptive for men on the market.
As hospitals face consolidation and CIOs are asked to increase staff productivity, tech companies that can support automation with solutions that are easy to onboard are getting heightened interest.
By Marissa Plescia Wednesday, November 9, 2022 5:17 PM
More than 31% of people with employer-sponsored insurance stuck with a job they disliked for the company's health insurance, a Forbes Advisor survey found. Another 8% of respondents left a job they liked to seek better coverage.
By Marissa Plescia Wednesday, November 9, 2022 4:36 PM
A customer of Cost Plus Drugs received an email from the company in October stating that "due to skyrocketing demand," shipping times have been delayed. Marley Drug, a competitor, said its company has not experienced delays and presented itself as an alternative for Americans.
By Katie Adams Wednesday, November 9, 2022 3:59 PM
Telemedicine company TytoCare launched a new offering that promises to give providers and health plans the range of products and services needed to operate successful virtual primary care programs. Gilad said the offering, named Home Smart Clinic, can give customers a clear picture of ROI because of its high utilization and patient engagement rates.
By Calum Yacoubian Wednesday, November 9, 2022 1:32 PM
With these APIs, data scientists, developers and analysts can free themselves from frustrating, tedious, and manual efforts to code and clean unstructured data. This is particularly valuable in healthcare where as much as 80% data is locked in unstructured text.
By Frank Vinluan Wednesday, November 9, 2022 1:10 PM
Amgen posted positive Phase 2 data for olpasiran, further building the case for the drug's blockbuster potential in heart disease as it proceeds to a pivotal test. Arrowhead Pharmaceuticals, which originally developed olpasiran and licensed it to the big pharma company, is cashing in now by selling its royalty rights to the molecule.
By Scott Musial Wednesday, November 9, 2022 9:00 AM
Requiring that PBMs bid on a per member per month guarantee would reduce the employer's uncertainty by securing the actual per member per month cost to the employer.
Today, the pharmaceutical industry is undergoing a rapid and dynamic transformation. Successful contract management plays an instrumental role in navigating this landscape.
No comments